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Research Article
A randomized placebo-controlled
pilot study of the efficacy and safety
of D-cycloserine in people with
chronic back pain
Thomas J Schnitzer, MD, PhD1, Souraya Torbey, MD2,
Kristi Herrmann, BS3, Gagan Kaushal, PhD4, Renita Yeasted, BS1
and A Vania Apkarian, PhD3
Abstract
Background: Few effective pharmacological treatment options exist for chronic back pain, the leading cause of disability in
the US, and all are associated with significant adverse effects.
Objective: To determine the efficacy and safety of D-cycloserine, a partial agonist to the N-methyl-D-aspartate receptor, in
the treatment of chronic low back pain.
Methods: A total of 41 participants with chronic back pain who met all inclusion and exclusion criteria were enrolled in a
double-blind, placebo-controlled randomized pilot trial of D-cycloserine. Treatment was administered orally for six weeks at
escalating daily doses of 100mg, 200mg, and 400mg, each for two weeks. The primary outcome measure was back pain
intensity using the Numeric Rating Scale (0–10). Secondary measures were back pain-related questionnaires: McGill Pain
Questionnaire short form, painDETECT, PANAS, and BDI. The pre-specified analysis was a two-way repeated measures
analysis of variance.
Results: A treatment difference was observed between groups treated with D-cycloserine and placebo at six weeks of
1.05 3.1 units on the Numeric Rating Scale, with an effect size of 0.4 and p¼ 0.14. This trend of better chronic back pain
relief with D-cycloserine was also observed in the secondary measures. No safety issues were seen.
Conclusion: The difference in mean pain between the D-cycloserine and placebo groups did not reach statistical signifi-
cance. However, a clinically meaningful effect size in the magnitude of pain relief was observed with a consistent pattern
across multiple outcome measures with good safety, supporting further research into the effectiveness of D-cycloserine for
chronic back pain.
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Background
Chronic pain remains a huge medical and societal
burden. Its incidence rate continues to rise, and chronic
back pain (CBP) remains the most prevalent chronic
pain condition. Recent epidemiological studies indicate
that the CBP is the leading source of disability in the US
and the seventh leading source worldwide.1 Despite a
long list of available pharmacological and management
strategies, a signiﬁcant percentage of CBP patients
remains dissatisﬁed with their levels of pain relief, and
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the World Health Organization states that no available
treatments are superior to each other.2 Moreover, the
most commonly used pharmacological options (nonster-
oidal anti-inﬂammatory drugs [NSAIDs], gabapentin,
duloxetine, and opiates) have important adverse eﬀects
and are not tolerated for long periods of use.3 Thus,
there is an urgent need to develop novel pain manage-
ment options especially for CBP.
D-cycloserine (DCS) is an established, FDA-
approved antimicrobial agent, recommended to be used
at doses up to 1000mg/day for the treatment of tuber-
culosis in the US and widely used throughout the world
as a second-line agent for that disease.4 In addition, it is
a partial agonist to the N-methyl-D-aspartate receptor in
the central nervous system and at high doses can lead to
drowsiness, dizziness, and convulsions.5 In rodents, oral
DCS has been shown to decrease pain-like behaviors in
multiple models of chronic pain (spared nerve injury,
and chemotherapy-induced neuropathy), in a dose
dependent manner, with eﬃcacy increasing with longer
duration use.6 Moreover, animals already treated with
DCS, when re-treated showed larger alleviation and
longer duration persistence of alleviation of neuropathic
pain, and when treated for about 30 days, post-treatment
alleviation of symptoms persists for more than an add-
itional 30 days.6 Although at the doses tested, DCS in
neuropathic rats relieved pain-like symptoms by only
about 50%, the emotional impact of the neuropathic
condition seemed completely eliminated (i.e., animals
behaved as if the remaining pain does not bother
them). It seems that in neuropathic rodents DCS does
not change stimulus sensitivity for body parts outside of
the injury, and acute or single doses of DCS do not alle-
viate neuropathic pain. Therefore, in the rodent DCS
does not act as a short-term analgesic; instead, it reduces
neuropathic pain and seems to largely eliminate asso-
ciated negative aﬀect.
The initial study of DCS in the rat described above
was in fact a reverse translational eﬀort, as it was based
on the evidence that brain imaging studies in CBP
patients had shown that chronic pain preferentially acti-
vates the medial prefrontal cortex (mPFC) and the
amygdala,7 and DCS administration systemically or
centrally (within mPFC or amygdala) in the rodent
facilitates fear extinction,8 and that mPFC is critical in
the rodent extinction of fear.9,10 More recent studies pro-
vide strong additional evidence regarding the role of
mPFC in human chronic pain11–16 and its interaction
with subcortical limbic structures most notably hippo-
campus, amygdala, and nucleus accumbens,14–18 as well
as rodent evidence showing that direct manipulation of
components of this circuitry either disrupts or modulates
persistent pain behavior.18–23 We have hypothesized that
chroniﬁcation of pain critically depends on brain
memory circuitry24 and DCS enhances cognitive and
memory processes and especially fear extinction10,25,26
through prefrontal limbic circuitry and reduces persistent
pain in the rodent.6 We therefore undertook the present
forward translational pilot study to speciﬁcally test the
eﬃcacy and safety of DCS in reducing back pain in CBP,
utilizing dosages that were well below those resulting in
signiﬁcant clinical side eﬀects.
Methods
This study was a pilot trial of DCS in subjects with
chronic low back pain, designed as a double-blind, par-
allel-group randomized clinical trial. The study was con-
ducted in compliance with the Declaration of Helsinki
and registered at clinicaltrials.gov (NCT00125528). The
protocol and informed consent documentation were
reviewed and approved by the Northwestern University
Institutional Review Board. Subjects provided written
informed consent before protocol-speciﬁed procedure
initiation. No external funding was provided for this
study.
Study population
Eligible subjects had to be between the ages of 18 and
75 years, have low back pain for a minimum of six
months, with or without radiation of pain to buttocks
or legs, and be in stable medical health. Subjects had to
rate their back pain at baseline as 55 out of 10 on the
Numeric Rating Scale (NRS; 0–10 scale) and be willing
to abstain from alcohol consumption during the course
of the study. Females had to be post-menopausal or, if of
child-bearing potential, use a highly eﬀective method of
contraception or abstinence and plan to continue during
the course of the study. Exclusion criteria included low
back pain associated with any systemic signs or symp-
toms; evidence of rheumatoid arthritis, ankylosing spon-
dylitis, acute vertebral fractures, ﬁbromyalgia, history of
surgery or tumor in the back; involvement in litigation
regarding their back pain or having a disability claim or
receiving workman’s compensation or seeking either;
neurologic or major psychiatric disorder; history of, or
current, substance abuse/dependence including alcohol;
signiﬁcantly abnormal laboratory values; known sensi-
tivity to DCS; currently taking any of the following
medications: ethionamide, dilantin, isoniazid (INH),
pyridoxine (vitamin B6); any change in medication for
back pain in the last 30 days.
Study design
This was a parallel group, randomized, double-blind,
placebo-controlled, dose-escalation clinical trial that
aimed to enroll 40 participants with low back pain.
There were ﬁve study visits overall: a screening visit, a
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baseline assessment and visits every two weeks thereafter
for six weeks after initiation of study medication.
Randomization occurred at the baseline visit in a 1:1
ratio with assignment to either DCS 50mg bid or match-
ing placebo, respectively. The randomization sequence
was generated by computer-generated program, and par-
ticipants received the next available number and num-
bered container(s) when they qualiﬁed. No study staﬀ
had access to the randomization sequence, and medica-
tion assignment and labeling were done by non-study
staﬀ. All study staﬀ and participants were blinded to
medication assignment until database lock. Participants
were required to continue their current medications for
low back pain throughout the course of the study. After
two weeks of study medication, all participants received
an increase in their assigned study medication to DCS
100mg bid or matching placebo. All study medication
was identical in appearance and formulated by the
University of Charleston School of Pharmacy from com-
mercially available DCS (Chao Center for Industrial
Pharmacy and Contact Manufacturing, West Lafayette,
IN) under IND 71528. This medication regime was con-
tinued for two weeks when assigned study medication
was again increased to either DCS 200mg or placebo
to be taken twice daily. These dosages were based on
the preclinical rat studies which demonstrated eﬃcacy
at low overall doses of DCS. Dose escalation was under-
taken after two weeks as that was felt as an adequate
length of time to reach a new steady-state and observe
eﬃcacy; continued escalation was designed in an attempt
to maximize the chances of detecting eﬃcacy while limit-
ing side eﬀects. Study capsules were all identical in
appearance. Randomization was in blocks of four by
use of a computer-generated list that was accessible to
study staﬀ only in case of drug-related study emergency.
Eﬃcacy and safety were assessed at baseline and at each
subsequent study visit. Acetaminophen rescue medica-
tion was allowed and limited to 500mg qid. All visits
and data collection took place at Northwestern
University Feinberg School of Medicine between July
2012 and April 2014.
Efficacy evaluation
At each visit, the following instruments were completed
by each subject: NRS (0–10mm scale; no pain to worst
possible pain); McGill Pain Questionnaire (short-form,
MPQ); Neuropathy Pain Scale (NPS); Pain Detect
Questionnaire; and Positive and Negative Aﬀect
Schedule (PANAS).
Safety evaluation
At each visit, participants were asked about changes in
health status and medications. Adverse events were
recorded and evaluated. The Beck Depression
Inventory (BDI) was administered at each visit.
Statistical methods
Sample size calculation. With 20 participants in the active
group and 20 in the placebo group, there will be 88%
power to detect an eﬀect size of 1.0, reﬂecting a diﬀerence
of 1.5 units on the NRS scale between the mean pain in
the active and placebo groups, with an alpha of 0.05 and
a standard deviation in both groups of 1.5 units, using a
two-sided test. With a smaller diﬀerence of 1.0 units on
the NRS scale (eﬀect size¼ 0.7), which is still clinically
meaningful, and with an alpha of 0.10 for this pilot study
and the remaining parameters remaining unchanged, the
power is reduced to 68%. The sample size was limited by
the availability of funding.
Outcome measures. The primary outcome measure was
the diﬀerence between the mean change from baseline
in the NRS pain score at week 6 in the active group
compared to the placebo group. Secondary outcome
measures included similar paired comparisons of each
of the eﬃcacy instruments (BPI, Roland-Morris
Disability Scale, SF-36, PANAS, BDI, MPQ, NPS,
Pain Detect Questionnaire) at the six-week time point
as well as at all other times measured.
Analysis. The pre-speciﬁed analysis was a two-way
repeated measures analysis of variance (two-way rm-
ANOVA) for the primary outcome measure NRS, with
repeated measure of time and treatment type (DCS or
placebo) as the independent factor, and with planned
post-hoc comparison between baseline and end of treat-
ment, contrasting between treatment types. All second-
ary outcome measures were also pre-speciﬁed to undergo
the same type of analysis.
Imputation. NRS and all questionnaires were collected at
visits 1–5. We averaged for visits 1 and 2 outcomes when-
ever available, otherwise we used visit 2 outcomes. In the
questionnaire, outcomes less than 5% of individual
queries were left unanswered. We replaced these missing
values by the same subject’s values from the previous
visit (imputation was performed for 57 of a total of
957 entries). The procedure enabled performing a
repeated-measures analysis of variance, and only minim-
ally changed group averages.
Results
Demographics
There were initially 41 subjects enrolled into the study,
21 assigned to the placebo group, and 20 to DCS
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treatment (See Consort Flow Chart, Figure 1). The
demographics of the two groups were similar with a
mean age at baseline of 53.2 11.4 years versus
53.3 10.7 years in the DCS and placebo groups,
respectively. Fourteen subjects in the DCS group and
11 subjects in the placebo group were female. There
was no signiﬁcant diﬀerence in racial or ethnic back-
grounds in the two groups, and no statistically signiﬁcant
diﬀerences in any of the other measures (Table 1). Three
subjects withdrew consent prior to receiving study medi-
cation; all other subjects completed the study.
Primary outcome
Both groups showed a reduction in pain magnitude over
the course of the study, but the diﬀerence between groups
did not reach statistical signiﬁcance. The absolute measure
of NRS was not diﬀerent between treatment groups (two-
way rm- ANOVA; Time eﬀect F3,108¼ 10.1, p< 0.01, but
no time-by-treatment interaction F3,108¼ 0.61, p> 0.60)
(Figure 2(a)). We obtained a similar result when we com-
pared within subject change in NRS scores (current NRS
score – baseline NRS score) over time (Figure 2(b)).
However, the post-hoc test indicates a signiﬁcant decrease
in NRS for DCS treatment between baseline and six-week
treatment (Fisher LSD test, p< 0.01), but not for placebo
treatment.
Secondary measures
For the MPQ aﬀective score (Figure 3(a)), there was a
large time eﬀect (F3,108¼ 6.9, p< 0.01) and borderline
time-by-treatment interaction eﬀect (F3,108¼ 1.5,
p< 0.20). Post-hoc analysis showed a signiﬁcant decrease
in MPQ aﬀective score for DCS treatment between base-
line and six-week treatment (Fisher LSD test, p< 0.01),
but not for placebo treatment. A similar but slightly
smaller eﬀect was observed for MPQ sensory outcome
(Figure 3(b)). The MPQ sensory outcome showed a time
eﬀect (F3,108¼ 2.96, p< 0.04) but no treatment-by-time
Assessed for eligibility (n=70  ) 
Excluded  (n=29 ) 
♦ Not meeting inclusion criteria (n=13) 
♦ Declined to participate (n=7) 
♦ Other reasons (n=9) 
Analyzed  (n= 18) 
Lost to follow-up (n=0) 
Allocated to DCS (n=20  ) 
♦ Received allocated intervention (n=18)
♦ Did not receive allocated intervention 
(withdrew consent) (n=2)
Lost to follow-up (n= 0) 
Allocated to placebo (n=21  ) 
♦ Received allocated intervention (n=20)
♦ Did not receive allocated intervention 
(withdrew consent) (n=1)






Figure 1. Consort diagram.
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interaction (F3,108¼ 0.5, p> 0.60. However post-hoc
analysis showed a signiﬁcant decrease in score for DCS
treatment between baseline and six-week treatment
(Fisher LSD test, p< 0.01), but not for placebo
treatment.
We observed a similar but stronger DCS eﬀect with
the painDETECT outcome measure (Figure 3(c)). There
was a large time eﬀect (F3,108¼ 7.8, p< 0.01) and bor-
derline time-by-treatment interaction eﬀect (F3,108¼ 1.9,
p< 0.14), and for post-hoc there was a signiﬁcant
decrease in painDETECT score for DCS treatment
between baseline and six-week treatment (Fisher LSD
test, p< 0.01), but not for placebo treatment. The
PANAS positive scale (Figure 3(d)) showed an overall
time eﬀect (F3,108¼ 3.61, p< 0.02) and a borderline treat-
ment-by-time interaction eﬀect (F3,108¼ 1.5, p¼ 0.20).
Post-hoc analysis indicated that DCS treatment
improved outcome at six weeks relative to baseline
(Fisher LSD p< 0.01) but not for placebo. In contrast,
PANAS negative showed no modulation (no eﬀect of
treatment, time or their interaction F3,108¼ 0.79,
p> 0.45). Similarly, treatment over six weeks did not
modulate BDI scores (no eﬀect of treatment, time or
their interaction F3,108¼ 0.65, p> 0.50).
Adverse effects
No serious adverse eﬀects were reported during the trial
in either group. The most common adverse events were
Table 1. Participant demographics.
DCS Placebo
Age (years) 53.2 11.4 53.3 10.7








BMI 33.9 11.8 30.1 6.2
Back pain duration (years) 10.7 7.8 8.7 9.0
Educational level
Through high school 45.0% 33.3%









DCS: D-cycloserine; BMI: body mass index; APAP: acetaminopen; NSAID:
nonsteroidal anti-inflammatory drug.
Figure 2. Back pain intensity ratings over a six-week, dose escalating, placebo or DCS treatment in CBP. (a) Across subject average
back pain, assessed on the primary outcome measure of 0–10 numeric rating scale. (b) Within subject change in pain, relative to baseline,
using the 0–10 numeric rating scale. Error bars are SEMs.
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headache (3/21 in the placebo group; 1/20 in the
DCS group), numbness and/or tingling (3/20 in the
DCS group and 0/21 in the placebo group), and lower
extremity edema (2/21 in the placebo group, 0/20 in the
DCS group). All adverse eﬀects were rated mild in
severity.
Discussion
In subjects with chronic low back pain in this study, we
observed a consistent pattern of the eﬀect of DCS, in
contrast to placebo, on a number of clinically important
outcome measures. Although neither the primary out-
come nor secondary outcomes showed an overall statis-
tically signiﬁcant time by treatment eﬀect, they all
showed trends, and the primary outcome measure as
well as the four secondary outcomes indicated signiﬁcant
post-hoc eﬀect of DCS at six weeks relative to baseline
with no eﬀect of placebo. Given the limited number of
subjects included in the studied, these results are stronger
than we had expected. Moreover, we observed that at six
weeks at a dose of 200mg DCS treatment, the eﬀect size
of pain relief was 0.4, a magnitude at least comparable to
eﬃcacy of NSAIDs reported for chronic low back
pain.27 For two outcome measures, placebo and DCS
eﬀects were not diﬀerent at two weeks and at four
weeks of treatment, but all ﬁve outcomes showed at six
weeks a larger eﬀect in the DCS group than in the pla-
cebo group. As the trial was a dose escalating regimen,
with stepwise increases every two weeks, and given that
rodent results indicated that continued treatment with
DCS over many weeks potentiates its eﬃcacy for anal-
gesia in neuropathic animals,6 these results cannot diﬀer-
entiate whether the observed eﬃcacy of DCS is due to
Figure 3. Back pain related secondary outcome measures showing improved back pain with six-week DCS treatment. (a) Affective score
of McGill Pain Questionnaire short form (sf-MPQ). (b) sf-MPQ sensory score. (c) Pain DETECT. (d) PANAS positive affect score. All
measures indicate a trend or significant improvement with DCS in comparison to placebo. Error bars are SEMs.
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dose escalation or simply a reﬂection of continued drug
consumption. Yet, taking into consideration the earlier
rodent results,6 we expect that continuation of DCS
treatment for longer periods should result in even
larger eﬀect sizes. As expected from a recent review of
the DCS literature,28 we observed minimal side eﬀects of
DCS consumption across all three doses and for up to six
weeks of treatment. Therefore, the present results suggest
that DCS may be a viable treatment for CBP, as it dem-
onstrates minimal side eﬀects and suggestive evidence
that it might be eﬃcacious in ameliorating back pain
intensity in low back pain patients. However, larger
population and longer duration treatment trials are the
next necessary steps that remain to be done.
The original study where DCS was demonstrated to be
eﬀective in ameliorating neuropathic pain in rodents6
demonstrated not only that DCS reduces tactile sensitivity
for the paw with neuropathic injury but also showed com-
plete reversal of place avoidance, when paw mechanical
stimulation was competed with the aversiveness of a white
compartment. This result suggests that DCS diminishes
the negative emotional load of neuropathic pain much
more than its sensory component. Somewhat consistent
with this observation, the current study showed an
increase in PANAS positive scores at six weeks of DCS
treatment (with no change in PANAS negative scores),
which suggests improvement in positive emotional
aﬀect, reﬂecting higher energy, more pleasurable engage-
ment, and increased extroversion. Thus, improved mood
accompanied with decreased pain seem to also have been
observed in the chronic low back pain patients.
The original study of DCS reducing neuropathic pain
also showed that the primary site of action of DCS was
through the glycine partial agonist site on the N-methyl-
D-aspartate receptor localized speciﬁcally in the pre-
limbic portion of the mPFC, with no eﬀects on multiple
other regions most importantly within the spinal cord.6
An observation that is important to consider given that
three recent studies show that manipulating activity or
excitability of pre-limbic neurons can completely reverse
neuropathic pain-like behavior in rodents.23,29,30 Thus,
we surmise that in the current trial as well DCS eﬀects
for relieving back pain were being mediated through
the same mechanism and brain pathway as observed in
the rodent.
Limitations of this study include the small sample size,
and the relatively short follow-up period available. In a
condition such as CBP, longer follow up would be ideal
to evaluate maintenance of pain-relief beneﬁt, and a
larger number of subjects would allow evaluation of
whether there were subgroups of individuals with CBP
who might respond in a diﬀerential manner to DCS.
Additionally, because of the dose-titration design,
it was not possible to diﬀerentiate a dosage from
time eﬀect.
Conclusion
Although the current study remains preliminary and
exploratory in nature, the obtained results imply further
studies of DCS as a treatment option for chronic pain
are warranted. Future studies should consider longer
duration treatments as well as assess post-treatment ces-
sation persistence of pain relief.
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